Articles related to ANTIDEPRESSANTS

N-nitroso-duloxetine poses increased cancer risk at higher concentrations and extended exposure periods, prompting FDA-mandated strict limits on nitrosamine levels in medications.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”

A new network meta-analysis reveals that high-dose psilocybin may be as effective as escitalopram for treating depressive symptoms, with a standardized mean difference of 0.31 compared to placebo in antidepressant trials.

Clinicians treating cancer and kidney disease patients prescribed antidepressants at rates similar to outpatient psychiatrists, highlighting the prevalence of depression management across specialties.

This target trial emulation study provides critical insights into weight change associated with eight first-line antidepressants, emphasizing the minimal weight gain with bupropion. Clinicians should integrate these findings into treatment decisions to address patient concerns about weight gain.

Clinicians should be vigilant about melatonin interactions with various medications such as antidepressants, blood thinners, and blood pressure drugs to ensure patient safety and effective treatment.